Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand?
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
El-Khouly Fatma E, Veldhuijzen van Zanten Sophie E M, Santa-Maria Lopez Vicente, Hendrikse N Harry, Kaspers Gertjan J L, Loizos G, Sumerauer David, Nysom Karsten, Pruunsild Kaie, Pentikainen Virve, Thorarinsdottir Halldora K, Rutkauskiene Giedre, Calvagna Victor, Drogosiewicz Monika, Dragomir Monica, Deak Ladislav, Kitanovski Lidija, von Bueren Andre O, Kebudi Rejin, Slavc Irene, Jacobs Sandra, Jadrijevic-Cvrlje Filip, Entz-Werle Natacha, Grill Jacques, Kattamis Antonis, Hauser Peter, Pears Jane, Biassoni Veronica, Massimino Maura, Lopez Aguilar Enrique, Torsvik Ingrid K, Joao Gil-da-Costa Maria, Kumirova Ella, Cruz-Martinez Ofelia, Holm Stefan, Bailey Simon, Hayden Tim, Thomale Ulrich W, Janssens Geert O R, Kramm Christof M, van Vuurden Dannis G
Аннотация
METHODS: Healthcare professionals specialized in DIPG were asked to fill in an online survey with questions regarding usual treatment strategies at diagnosis and at disease progression in their countries and/or their centers, respectively.
RESULTS: Seventy-four healthcare professionals responded to the survey, of which 87.8% were pediatric oncologists. Only 13.5% of the respondents biopsy all of their patients, 41.9% biopsy their patients infrequently. More than half of the respondents (54.1%) treated their patients with radiotherapy only at diagnosis, whereas 44.6% preferred radiotherapy combined with chemotherapy. When the disease progresses, treatment strategies became even more diverse, and the tendency for no treatment increased from 1.4% at diagnosis to 77.0% after second progression. 36.5% of the healthcare professionals treat children younger than 3 years differently than older children at diagnosis. This percentage decreased, when the disease progresses. Most of the participants (51.4%) included less than 25% of their patients in clinical trials.
CONCLUSION: This survey demonstrates a large heterogeneity of treatment regimens, especially at disease progression. We emphasize the need for international consensus guidelines for the treatment of DIPG, possible by more collaborative clinical trials.